Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-1.11%)
USD 0.01
(-1.11%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 10.55 Million USD | -58.06% |
| 2022 | 25.16 Million USD | 30.81% |
| 2021 | 19.23 Million USD | -82.51% |
| 2020 | 109.96 Million USD | 288.65% |
| 2019 | 28.29 Million USD | 605.61% |
| 2018 | 4.01 Million USD | -2.64% |
| 2017 | 4.11 Million USD | -67.86% |
| 2016 | 12.81 Million USD | -68.05% |
| 2015 | 40.11 Million USD | -47.84% |
| 2014 | 76.89 Million USD | 1597.43% |
| 2013 | 4.53 Million USD | -64.67% |
| 2012 | 12.82 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 8.21 Million USD | -22.14% |
| 2024 Q2 | 8.55 Million USD | 4.06% |
| 2023 FY | 10.55 Million USD | -58.06% |
| 2023 Q2 | 14.07 Million USD | -45.94% |
| 2023 Q3 | 13.32 Million USD | -5.34% |
| 2023 Q4 | 10.55 Million USD | -20.78% |
| 2023 Q1 | 26.03 Million USD | 3.46% |
| 2022 Q4 | 25.16 Million USD | -40.49% |
| 2022 Q2 | 53.47 Million USD | 54.68% |
| 2022 Q1 | 34.57 Million USD | 79.71% |
| 2022 FY | 25.16 Million USD | 30.81% |
| 2022 Q3 | 42.28 Million USD | -20.93% |
| 2021 Q2 | 108.74 Million USD | 16.35% |
| 2021 Q1 | 93.46 Million USD | -15.01% |
| 2021 Q3 | 67.42 Million USD | -38.0% |
| 2021 Q4 | 19.23 Million USD | -71.47% |
| 2021 FY | 19.23 Million USD | -82.51% |
| 2020 FY | 109.96 Million USD | 288.65% |
| 2020 Q3 | 112.32 Million USD | -16.83% |
| 2020 Q4 | 109.96 Million USD | -2.1% |
| 2020 Q2 | 135.05 Million USD | 763.25% |
| 2020 Q1 | 15.64 Million USD | -44.71% |
| 2019 Q4 | 28.29 Million USD | -27.43% |
| 2019 Q2 | 54.41 Million USD | 1582.59% |
| 2019 Q1 | 3.23 Million USD | -19.35% |
| 2019 FY | 28.29 Million USD | 605.61% |
| 2019 Q3 | 38.98 Million USD | -28.35% |
| 2018 Q2 | 26.16 Million USD | 191.03% |
| 2018 Q3 | 15.02 Million USD | -42.58% |
| 2018 Q4 | 4.01 Million USD | -73.31% |
| 2018 FY | 4.01 Million USD | -2.64% |
| 2018 Q1 | 8.99 Million USD | 118.32% |
| 2017 FY | 4.11 Million USD | -67.86% |
| 2017 Q4 | 4.11 Million USD | -34.06% |
| 2017 Q3 | 6.24 Million USD | -23.95% |
| 2017 Q2 | 8.21 Million USD | -23.48% |
| 2017 Q1 | 10.73 Million USD | -16.26% |
| 2016 FY | 12.81 Million USD | -68.05% |
| 2016 Q1 | 25.53 Million USD | -36.34% |
| 2016 Q4 | 12.81 Million USD | -15.71% |
| 2016 Q3 | 15.2 Million USD | -32.66% |
| 2016 Q2 | 22.58 Million USD | -11.57% |
| 2015 Q1 | 71.92 Million USD | -6.47% |
| 2015 Q3 | 52.67 Million USD | -17.95% |
| 2015 Q4 | 40.11 Million USD | -23.84% |
| 2015 FY | 40.11 Million USD | -47.84% |
| 2015 Q2 | 64.19 Million USD | -10.75% |
| 2014 Q3 | 16.18 Million USD | 0.0% |
| 2014 FY | 76.89 Million USD | 1597.43% |
| 2014 Q4 | 76.89 Million USD | 375.11% |
| 2013 FY | 4.53 Million USD | -64.67% |
| 2013 Q4 | 4.53 Million USD | 0.0% |
| 2012 FY | 12.82 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -456783.117% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -438.967% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1811.541% |
| Rebus Holdings, Inc. | 5000.00 USD | -210980.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 91.895% |
| Qrons Inc. | 420.00 USD | -2512757.143% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1269.504% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 62.232% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2096.201% |
| Skye Bioscience, Inc. | 11.94 Million USD | 11.611% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 72.832% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -46.182% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -13722.459% |
| SQZ Biotechnologies Company | 107.18 Million USD | 90.154% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -636.995% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -14484.399% |
| Mesoblast Limited | 667.9 Million USD | 98.42% |
| Marizyme, Inc. | 22.01 Million USD | 52.06% |
| Genus plc | 1.02 Billion USD | 98.974% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -676.97% |
| Pharming Group N.V. | 462.85 Million USD | 97.72% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -218.562% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2014.865% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1583.254% |
| ContraFect Corporation | 20.67 Million USD | 48.963% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2603.617% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2661.548% |
| IMV Inc. | 31.33 Million USD | 66.318% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -154.557% |
| MultiCell Technologies, Inc. | 126.22 USD | -8361490.873% |
| ONE Bio Corp. | 70.08 Million USD | 84.941% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1023.138% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 91.787% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2344.674% |
| Q BioMed Inc. | 3.51 Million USD | -200.212% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 69.999% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3939.391% |
| Biomind Labs Inc. | 73.81 Thousand USD | -14197.132% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.635% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -628.443% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 64.838% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -284.294% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1435.159% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -305.425% |
| GB Sciences, Inc. | 103.44 Thousand USD | -10102.819% |
| Alpha Cognition Inc. | 2.45 Million USD | -330.394% |
| HST Global, Inc. | 1526.00 USD | -691512.058% |
| CSL Limited | 38.02 Billion USD | 99.972% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -968.254% |
| Halberd Corporation | 10.13 Thousand USD | -104075.304% |
| Enzolytics Inc. | 361.7 Million USD | 97.082% |
| Agentix Corp. | 261.39 Thousand USD | -3937.614% |
| Resverlogix Corp. | 8.11 Million USD | -30.055% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -462.017% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.768% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 77.875% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1549.949% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -46228.08% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -17.933% |
| AVAX Technologies, Inc. | 7.37 Million USD | -43.063% |
| Zenith Capital Corp. | 7410.00 USD | -142329.15% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.688% |
| Ember Therapeutics, Inc. | 184.00 USD | -5735769.565% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -3179.616% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3938.047% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1037.332% |
| Kadimastem Ltd | 2.3 Million USD | -358.057% |
| Helix BioMedix, Inc. | 3.02 Million USD | -248.883% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 79.974% |
| BioStem Technologies, Inc. | 14.56 Million USD | 27.515% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -18385.305% |
| LadRx Corporation | 2.3 Million USD | -357.302% |
| Cell Source, Inc. | 195.17 Thousand USD | -5307.566% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2884.585% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2884.585% |
| NovAccess Global Inc. | 62.24 Thousand USD | -16854.762% |
| Affymax, Inc. | 7.44 Million USD | -41.798% |
| Itoco Inc. | 1.4 Million USD | -653.818% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -10933.171% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -9856.604% |
| Mobile Lads Corp. | 52.00 USD | -20296053.846% |
| CytoDyn Inc. | 11.13 Million USD | 5.226% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -7281.865% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -58926.846% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2637.949% |
| SYBLEU INC | 330.46 Thousand USD | -3093.653% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2477.78% |
| International Stem Cell Corporation | 5.39 Million USD | -95.807% |
| Bioxytran, Inc. | 137.63 Thousand USD | -7567.941% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 29.649% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 36.341% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -13259.494% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1120.571% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -40.402% |
| Neutra Corp. | 2851.00 USD | -370085.9% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 67.432% |
| PureTech Health plc | 693.97 Million USD | 98.479% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -30.763% |
| IXICO plc | 15.84 Million USD | 33.388% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -27.433% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 89.786% |
| CSL Limited | 38.02 Billion USD | 99.972% |
| Cellectis S.A. | 333.99 Million USD | 96.84% |